Raoul William, Chailley-Heu Bernadette, Barlier-Mur Anne-Marie, Delacourt Christophe, Maître Bernard, Bourbon Jacques R
Institut National de la Santé et de la Recherche Médicale Unité U492, Faculté de Médecine, Université Paris XII, 8 rue du Général Sarrail, 94010 Créteil, France.
Am J Physiol Lung Cell Mol Physiol. 2004 Jun;286(6):L1293-301. doi: 10.1152/ajplung.00157.2003. Epub 2004 Jan 23.
Previous investigations gained from in vivo or lung explant studies suggested that VEGF is an autocrine proliferation and maturation factor for developing alveolar type II cells. The objective of this work was to determine whether VEGF exerted its growth and maturation effects directly on isolated type II cells. These were isolated from 19-day fetal rat lung and cultured in defined medium. The presence of VEGF receptor-2 was assessed in cultured cells at the pre- and posttranslational levels. Recombinant VEGF(165), formerly found to be active on lung explants, failed to enhance type II cell proliferation estimated by thymidine and 5-bromo-2'-deoxy-uridine incorporation. It increased choline incorporation in saturated phosphatidylcholine by 27% but did not increase phospholipid surfactant pool size. VEGF (100 ng/ml) left unchanged the transcript level of surfactant proteins (SP)-A, SP-C, and SP-D but increased SP-B transcripts to four times the control steady-state level. VEGF slightly retarded, but did not prevent, the in vitro transdifferentiation of type II into type I cells, as assessed by immunolabeling of the type I cell marker T1alpha. We conclude that, with the exception of SP-B expression, which appears to be controlled directly, the previously observed effects of this VEGF isoform on type II cells are likely to be exerted indirectly through reciprocal paracrine interactions involving other lung cell types.
先前通过体内或肺外植体研究获得的调查表明,血管内皮生长因子(VEGF)是正在发育的肺泡II型细胞的自分泌增殖和成熟因子。这项工作的目的是确定VEGF是否直接对分离出的II型细胞发挥其生长和成熟作用。这些细胞从19天龄的胎鼠肺中分离出来,并在特定培养基中培养。在翻译前和翻译后水平评估培养细胞中VEGF受体-2的存在情况。先前发现对肺外植体有活性的重组VEGF(165),未能通过胸苷和5-溴-2'-脱氧尿苷掺入来增强II型细胞增殖。它使饱和磷脂酰胆碱中的胆碱掺入增加了27%,但没有增加磷脂表面活性剂池的大小。VEGF(100 ng/ml)使表面活性蛋白(SP)-A、SP-C和SP-D的转录水平保持不变,但使SP-B转录本增加到对照稳态水平的四倍。通过I型细胞标志物T1α的免疫标记评估,VEGF略微延迟但未阻止II型细胞在体外向I型细胞的转分化。我们得出结论,除了似乎直接受控制的SP-B表达外,先前观察到的这种VEGF异构体对II型细胞的作用可能是通过涉及其他肺细胞类型的相互旁分泌相互作用间接发挥的。